Health knowledge made personal
Join this community!
› Share page:
Search posts:

A Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV-1 Strains

Posted Apr 30 2012 8:00pm

Description of Invention:
This Human Anti-HIV Monoclonal Antibody (10E8) has great potential to provide passive protection from infection, as a therapeutic vaccine, or as a tool for the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated thus far and it can potently neutralize up to 98% of genetically diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein, GP41. It is anticipated that 10E8 could be used in combination with another human anti-HIV-1 monoclonal antibody to provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 is a useful tool for the design of vaccine immunogens that can elicit an adaptive immune response to produces 10E8 like antibodies. This technology also includes monoclonal antibodies from the same germ line as 10E8.

  • Passive protection to prevent HIV infection
  • Passive protection to prevent mother-to-infant HIV transmission
  • Topical microbicide to prevent HIV infection
  • Gene-based vectors for anti-gp41 antibody expression
  • Therapeutic for the elimination of HIV infected cells that are actively producing virus

  • One of the most potent Human broadly-neutralizing anti HIV antibodies isolated to date
  • Broad reactivity and high affinity to most HIV-1 strains
  • Activity is highly complementary to existing broadly neutralizing antibodies, such as CD4 binding site antibodies
  • Capable of neutralizing all HIV-1 strains, if used in combination with another anti-HIV monoclonal antibody

Development Status:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)

Mark Connors (NIAID)

Patent Status:
HHS, Reference No. E-253-2011/0
US, Application No. 61/556,660 filed 07 Nov 2011

Related Technologies:
PCT, Application No. PCT/US2006/005613 filed 17 Feb 2006, Reference No. E-123-2005/1
US, Application No. 13/057,414 filed 03 Feb 2011, Reference No. E-291-2008/0
US, Application No. 61/086,098 filed 04 Aug 2008, Reference No. E-291-2008/0

Relevant Publication:
  1. In press

Collaborative Research Opportunity:
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine immunogens capable of eliciting a 10E8-like adaptive immune response. For collaboration opportunities, please contact Bill Ronnenberg at 301-451-3522 or .

For Licensing Information Please Contact:
Cristina Thalhammer-Reyero Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 33,
Rockville, MD 20852
United States
Phone: 301-435-4507
Fax: 301-402-0220

Ref No: 2428

Updated: 05/2012

Post a comment
Write a comment:

Related Searches